Selected 2002 Venture Capital Transactions as Company Counsel

Selected 2002 Venture Capital Transactions as Company Counsel

Publication

In 2002, Hale and Dorr served as company counsel in more than 150 venture financings raising more than $1.5 billion, including some of the largest and most prominent deals of the year. The following are selected 2002 transactions:

  • 170 Systems — $14 million
  • Acopia Networks — $10.5 million
  • Airvana — $40 million
  • Angiolink — $10.6 million
  • Arbor Networks — $22 million
  • BrassRing — undisclosed
  • CambridgeSoft — $3.2 million
  • Celarix — $17 million
  • Cognistar — $7.75 million
  • Critical Therapeutics — $10 million
  • Ecutel — $4.5 million
  • Ellacoya Networks — $16 million
  • Endius —$8.1 million
  • Équipe Communications — $40 million
  • Flexplay Technologies — $5 million
  • GenPath Pharmaceuticals — $15.5 million
  • Hydra Biosciences — $9.3 million
  • IE-Engine — $6.4 million
  • Infinity Pharmaceuticals — $70 million
  • Microbia — $26 million
  • Nauticus Networks — $26 million
  • netDecide — $6.5 million
  • Netezza — $20 million
  • Netilla Networks — $3.5 million
  • Next Century — $2 million
  • Pelago Networks — $25 million
  • PharMetrics — $7 million
  • Princeton eCom — $10 million
  • ReliCore — $14 million
  • Storability — $12 million
  • SRA International — $39.6 million
  • Surface Logix — $25 million
  • Syntonix Pharmaceuticals — $35.8 million
  • TAZZ Networks — $7.7 million
  • Tatara Systems — $8.5 million
  • Upromise — $12 million
  • XOsoft — $4 million

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.